CymitQuimica logo
Bcr-Abl

Bcr-Abl

Bcr-Abl inhibitors are targeted therapies that inhibit the Bcr-Abl fusion protein, which is formed due to the Philadelphia chromosome translocation and is a driver of chronic myeloid leukemia (CML). This protein also influences angiogenesis, contributing to tumor progression. Bcr-Abl inhibitors are crucial in the treatment of CML and are being explored for their potential in inhibiting angiogenesis in various cancers. At CymitQuimica, we provide high-quality Bcr-Abl inhibitors to support your research in cancer biology, angiogenesis, and targeted therapy.

Found 102 products of "Bcr-Abl"

Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
products per page.
  • HSN748
    Targetmol
    + Info

    HSN748

    CAS:
    <p>HSN748 is an analog of ponatinib and acts as a multi-kinase inhibitor. It exhibits inhibitory activity against kinases such as FLT3, ABL1, RET, PDGFRα/β, MNK1, and MNK2. HSN748 can suppress the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines, making it a useful compound in leukemia research.</p>
    Formula:C27H24F3N7O
    Color and Shape:Solid
    Molecular weight:519.521

    Ref: TM-T204396

  • BCR-ABL-IN-8
    Targetmol
    + Info

    BCR-ABL-IN-8

    CAS:
    <p>BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor featuring a trimethoxy group [1].</p>
    Formula:C30H33N7O5
    Purity:98%
    Color and Shape:Solid
    Molecular weight:571.63

    Ref: TM-T82909

    5mg
    Discontinued
    50mg
    Discontinued
    Discontinued product